Loading... Loading... Analysts' ratings for Ardelyx ARDX over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 2 0 0 0 3M Ago 2 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.0, with a high estimate of $15.00 and a low estimate of $13.00. This current average reflects an increase of 33.33% from the previous average price target of $10.50. Diving into Analyst Ratings: An In-Depth Exploration In examining recent analyst actions, we gain insights into how financial experts perceive Ardelyx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Roanna Ruiz Leerink Partners Announces Outperform $14.00 - Christopher Raymond Piper Sandler Raises Overweight $15.00 $12.00 Laura Chico Wedbush Maintains Outperform $13.00 - Laura Chico Wedbush Raises Outperform $13.00 $9.00 Yigal Nochomovitz Citigroup Raises Buy $14.00 $9.00 Steven Seedhouse Raymond James Raises Strong Buy $15.00 $12.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ardelyx. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ardelyx compared to the broader market. Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ardelyx's stock. This comparison reveals trends in analysts' expectations over time. For valuable insights into Ardelyx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table. Stay up to date on Ardelyx analyst ratings. If you are interested in following small-cap stock news and performance you can start by tracking it here . Loading... Loading... Delving into Ardelyx's Background Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis. Key Indicators: Ardelyx's Financial Health Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers. Decline in Revenue: Over the 3 months period, Ardelyx faced challenges, resulting in a decline of approximately -22.22% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers. Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -83.82%, the company showcases strong profitability and effective cost control. Return on Equity (ROE): Ardelyx's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -16.09%, the company may face hurdles in generating optimal returns for shareholders. Return on Assets (ROA): Ardelyx's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -9.81%, the company may face hurdles in generating optimal returns from its assets. Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34 . How Are Analyst Ratings Determined? Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs. This article was generated by Benzinga's automated content engine and reviewed by an editor. Loading... Loading...